We hypothesized that specific activation of a single retinoic acid receptor-a (RARa), without direct and concurrent activation of RARb and c, will inhibit mammary tumor oncogenesis in murine models relevant to human cancer. A total of 50 uniparous mouse mammary tumor virus (MMTV)-neu and 50 nuliparous MMTV-wnt1 transgenic mice were treated with RARa agonist (retinobenzoic acid, Am580) that was added to the diet for 40 (neu) and 35 weeks (wnt1), respectively. Among the shared antitumor effects was the inhibition of epithelial hyperplasia, a significant increase (Po0.05) in tumor-free survival and a reduction in tumor incidence and in the growth of established tumors. In both models, the mechanisms responsible for these effects involved inhibition of proliferation and survival pathways, and induction of apoptosis. The treatment was more effective in the MMTV-wnt1 model in which Am580 also induced differentiation, in both in vivo and threedimensional (3D) cultures. In these tumors Am580 inhibited the wnt pathway, measured by loss of nuclear b-catenin, suggesting partial oncogene dependence of therapy. Am580 treatment increased RARb and lowered the level of RARc, an isotype whose expression we linked with tumor proliferation. The anticancer effect of RARa, together with the newly discovered pro-proliferative role of RARc, suggests that specific activation of RARa and inhibition of RARc might be effective in breast cancer therapy.
Introduction
Vitamin A maintains the differentiated state of adult epithelia (Wolbach and Howe, 1978) . Its functional derivative, retinoic acid (RA), exerts an effect by binding to retinoid (RAR) and rexinoid family of nuclear receptors, which belong to a superfamily of ligand-dependent transcription factors. RARs and rexinoids (each a family of three genes, a, b and g, that give rise to multiple isoforms) function cooperatively through heterodimerization, actively repressing or activating target gene transcription (Chambon, 1996) . Retinoids have been shown to suppress cancer cell growth and prevent mammary cancer in carcinogen rodent models (Sporn et al., 1976; Moon and Mehta, 1990) , but success in clinical trials of breast cancer has been minimal at best (Astrom et al., 1990; Hong et al., 1990; Lotan, 1995; Shin et al., 2001; Wu et al., 2001) . The only exception is the remarkable efficacy of all-trans retinoic acid (atRA) in acute promyelocytic leukemia, in which durable remissions and increased survival have been achieved (Warrell et al., 1993; Collins, 2008; Patatanian and Thompson, 2008) . In this cancer, atRA specifically targets a fusion protein (PML-RARa) that, when present, functions by blocking normal differentiation (Wolf and Smas, 2000) . This suggests that once the functions of specific RARs in the context of defined oncogenic environment become identified, retinoids might become more broadly effective.
One such recently reported example shows that treatment of MMTV-neu mice with atRA was not only ineffective but was also counterproductive, increasing mammary tumor incidence and growth (Schug et al., 2007) . The researchers concluded that the outcome (cell growth arrest and differentiation versus cell proliferation) is determined by a balance between two atRA chaperones, CARBP-II and FABP5 (fatty acid-binding protein 5); predomination of the latter leads to activation of peroxisome proliferator-activated receptor (PPAR)b/d and cancer cell proliferation and survival.
In keeping with this idea and supported by a recent publication (Purton et al., 2006) , we propose that RARg, under certain conditions, has a pro-proliferative role and that its activation by atRA might be responsible for the limited success of retinoid treatment in human cancers. Thus, rather than using atRA, an activator of all three RAR isotypes, we tested the RARa agonist Am580, which has a 10-fold greater affinity for RARa than for b, is almost inactive against RARg (Delescluse et al., 1991) and is resistant to degradation by CYP26A1-P450 (White et al., 1997; Osanai and Petkovich, 2005) , for its effect on mammary carcinomas in two transgenic mouse models, mouse mammary tumor virus (MMTV)-neu and MMTV-wnt.
Neu (HER2/ErbB2) encodes a tyrosine kinase receptor that is amplified in B30% of human breast cancer and is associated with poor prognosis (Slamon et al., 1987) . The activation of neu leads to a cascade activation of kinases such as the src family, focal adhesion kinase, phosphoinositide 3-kinase/Akt, mitogen-activated protein kinase and possibly others, inducing cell growth and tumor formation (Dankort and Muller, 2000; Marcotte and Muller, 2008) . The MMTV-wnt1 is believed to target the mammary stem/progenitor compartment, as evidenced by tumors in which both epithelial and myoepithelial cells are present (Li et al., 2003) . Wnt gene encodes a family of secreted glycoproteins that bind to specific membrane receptors. Activation of the wnt pathway leads to stabilization of b-catenin and its translocation to the nucleus, in which it interacts with T-cell-specific transcription factor/ lymphoid enhancer-binding factor and induces gene expression, including genes involved in cell proliferation and survival such as c-myc (Nelson and Nusse, 2004) . The wnt family pathways, which are important in mammary development and renewal of stem cell in the adult tissue (Brennan and Brown, 2004; Clevers, 2006) , are often perturbed in tumors. Aberrant activation of the wnt pathway and epigenetic downregulation of wnt inhibitors has been reported in many tumors, including breast carcinomas (Bukholm et al., 2000; Lin et al., 2000; Ryo et al., 2001; Veeck et al., 2008a, b) . The effect of RA signaling on wnt, although complex, suggests some inhibitory effect (Easwaran et al., 1999) .
We found that Am580 treatment strongly inhibited the neu-and wnt1-induced mammary gland hyperplasia, the incidence of microscopic tumors, tumor growth and, in the neu model, strongly inhibited lung metastases, leading to a significant increase in tumor-free survival in both models. In addition to inhibiting tumor cell proliferation and increasing apoptosis, the mechanisms responsible for the AM580 inhibition of oncogenesis in both models, Am580 also induced differentiation, but only in MMTV-wnt1. This difference provides a potential explanation for the increased magnitude of the tumor-free survival found in MMTV-wnt1.
Overall, our data suggest that in two different models of mammary oncogenesis, by targeting specific RARs, it is possible to achieve antitumor effects that are partially universal and partially oncogene specific. These effects are, most likely, the result of activation of an inhibitory RARa and simultaneous reduction in RARg, which we showed to be pro-proliferative. We propose that treatment of breast cancer patients selected on the basis of oncogeneactivated pathway with RAR-specific retinoids might overcome the current difficulties with retinoid therapies.
Results

Am580 treatment reduces tumorigenesis in wnt1 and neu transgenic models
We used an RARa agonist retinobenzoic acid Am580 (Kagechika et al., 1988) , a compound with a 10-fold lower affinity for RARb (Delescluse et al., 1991) and no detectable affinity toward RARg, to treat transgenic mice with mammary cancer induced by wnt1 or neu (Muller et al., 1988; Tsukamoto et al., 1988) . We hypothesized that by evading RARg activation, we will lessen skin toxicity (Chapellier et al., 2002) and avoid the potential pro-proliferative tumor effects of RARg (Purton et al., 2006) .
A dose of 0.3 mg/kg/day of Am580 (suggested by Dr Koichi Shudo, who supplied the drug) was tested by treating 10 FVB mice for 4 months; no overt toxicity was found in the liver, lungs, kidney and spleen (results not shown). This dose of Am580, which was contained in the diet, was used to treat MMTV-neu and MMTV-wnt1 transgenic mice (control mice were fed the same diet without Am580). The mice were palpated twice weekly, the tumor appearance was recorded and the data were used to generate Kaplan-Meier tumor-free survival curves. Figures 1a and b show that tumor-free survival was significantly (log-rank test) increased in both MMTV-neu (Po0.05) and MMTV-wnt1 (Po0.01) mice treated with Am580; a dose of 0.1 mg/ kg/day produced similar but somewhat weaker effects (results not shown). The effect was more profound in the MMTV-wnt1 model, in which 50% of the untreated mice had palpable tumors at B22 weeks, whereas in the treated group o50% of mice had tumors as late as at week 35 ( Figure 1b) . The difference between the control and treated MMTV-neu mice was smaller, but even in this group the treatment increased the percentage of tumor-free mice from o10% in control to 30% in the treated group (Figure 1a ). The pronounced effect of Am580 after week 35 in the neu model might be because of the unique biology of the later appearing tumors or longer duration of the treatment.
Once palpable, the tumors in control and Am580treated mice (MMTV-neu: 40 control and 33 treated; MMTV-wnt1: 35 control and 26 treated) were measured weekly and the mice were killed when tumors reached B1.5 g. As shown in Figures 1c and d , in which zero represents the time the tumor was first palpable, the Am580 treatment significantly (Po0.01 and Po0.001 for neu and wnt, respectively) retarded tumor growth in both transgenic models. In approximately 80% of the MMTV-wnt1-treated mice, the tumors grew to B0.5 g, at which time they showed cycles of partial regression and re-growth ( Figure 1d ), possibly because of development of cysts that burst and re-grow; in approximately 10% the palpable tumors completely regressed (results not shown).
We found that neu mice have relatively high incidence of lung metastases and thus examined whether Am580 treatment, in addition to inhibiting tumorigenesis, will also affect the incidence of lung metastasis. As shown in Figure 1e , in a randomly selected group of 20 control and 20 treated mice, the treatment reduced the incidence of lung metastases from 75 to 35%. Because at the time of metastasis evaluation, the average size of the treated tumors was lower than control, it is impossible at this time to conclude that the observed metastasis reduction was a direct Am580 effect on this process.
Mechanisms that mediate the antitumor effects of Am580
To determine the mechanism through which Am580 reduces tumor growth and possibly increases tumor-free survival, we tested tumor sections for markers of proliferation and apoptosis. Sections from 10 control and 10 treated tumors were stained for retinoblastoma protein (pRb) as a marker of proliferation, and for p27, which is known to increase during cell cycle arrest and has been shown to accumulate in response to RAR activation (Borriello et al., 2006; Radu et al., 2008) . P27 is a regulator of pRb phosphorylation (Vidal and Koff, 2000) . As shown in Figure 2a , in both models, the Am580-treated tumors have a significantly higher p27 (Po0.001) levels and a significantly reduced level of pRb (Po0.01), suggesting a degree of proliferative arrest in both tumor models. However, although the reduction in pRb was observed in all the tested, Am580treated wnt1 tumors sections, it was detected in only 6/ 10 sections from treated neu tumors, suggesting a more consistent effect on MMTV-wnt1 tumors.
We used caspase-3 activation and TdT-mediated dUTP nick end labeling assay as markers of apoptosis and Akt phosphorylation as a measure of pro-survival pathway. A significant increase (Po0.01 and Po0.001 for neu and wnt, respectively) in caspase-3 activation by Am580 (Figure 2b) , as confirmed by TdT-mediated dUTP nick end labeling assay (results not shown), was found in both tumor types. However, although in MMTV-neu, caspase-3 was distributed randomly across the tumor tissue, in MMTV-wnt1 tumors, it was more localized to lumens of normal-looking acini structures, suggesting a possibility of cavitation and A total of 50 MMTV-neu (a) and MMTV-wnt1 (b) transgenic mice were treated with Am580 in the diet as described in Materials and methods. The Kaplan-Meier curves show a significant (Neu: Po0.05; Wnt: Po0.01, log-rank test) increase in tumor-free survival in Am580-treated transgenic mice. Tumor size ( ± s.e.) in MMTV-neu (c, analysis of variance (ANOVA) Po0.01) and MMTV-wnt1 (d, ANOVA Po0.001) was determined by twice weekly measurements; the appearance of palpable tumors is considered time zero. The experiment was terminated when the untreated tumors were B1.5 g (the variation in wnt tumor volume with time is most likely because of development of fluid-filled cysts that burst and refilled). (e) Surface lung metastases were counted using a stereoscope at the end of the experiment described in c. In all, 20 randomly selected untreated and 20 Am580-treated MMTV-neu mice were evaluated (t-test, Po0.001).
AM580 chemoprevention, oncogenes and negative RARc role Y Lu et al thus differentiation (Figure 2b ). This was confirmed in three-dimensional (3D) cultures of MMTV-wnt1 cells that were incubated with 50 nM AM580, or with medium alone for 13 days and stained for caspase-3. The treatment increased caspase-3 expression in all of the colonies, and in 30% of the colonies it induced (Figure 2d ). We quantified the Am580 effect on apoptosis using ethidium bromide staining (Gantenbein-Ritter et al., 2008) and showed that the treatment caused a significant increase (Figure 2e , t-test, Po0.001).
To examine the effect of Am580 treatment on survival pathway, protein extracts of randomly selected 12 tumors per group (neu control and treated and wnt control and treated) were prepared and analyzed for total Akt and P-Akt levels. Figure 2c , which shows three representative samples of these tumors, indicates that the treatment reduced P-Akt/Akt ratio by B50%, suggesting that the survival of tumor cells might be compromised by the treatment.
Oncogene-dependent effect of Am580
As shown in Figures 1a and b , Am580 treatment had a more profound effect on tumor-free survival of MMTV-wnt1 mice, with the effect being noticeable even in early appearing tumors. To test whether this was a reflection of Am580 treatment modifying more effectively the premalignant wnt-expressing glands, we examined whole mounts of those wnt and neu glands that, at the time of killing for tumor removal, were deemed tumor free by palpation. Both MMTV-neu and MMTV-wnt1 glands showed signs of focal hyperplasia, appearing as small patches, or as large areas that sometimes involved the entire mammary gland (Figure 3a, top ). An analysis of the whole mounts (n ¼ 40 per group) indicated that Am580 treatment reduced substantially and equally the level of hyperplasia in both transgenic glands (Figure 3a , bars; Fisher's exact test, neu *Po0.001 and wnt1 **Po0.0001). Analysis of whole-mount glands also revealed the presence of small, microscopic tumors (Figure 3b , top) that could not be detected by palpation; the total number of glands with small tumors (5 for wnt control, and 14 for neu control) and of glands with multiple small tumors (o2 mm in diameter; 0 for wnt and 4 for neu) was also significantly reduced by the Am580 treatment (Figure 3b , bars; Fisher's exact test, neu *Po0.001 and wnt **Po0.01). The similarity in the level of hyperplasia reversion and the reduction, by Am580, of the percentage of mice with microscopic tumors in both tumor models suggest that these effects are, most likely, not responsible for the more profound tumor-free survival effect of wnt1 mice.
We repeatedly noticed that sections of wnt-induced tumors, and especially Am580-treated wnt tumors, seem to be more differentiated than the neu tumors. Hematoxylin and eosin stained sections of untreated MMTV-neu showed the typical, poorly differentiated solid nodules with little stroma (Figure 3c , left upper panel), which were not changed by Am580 treatment, but for some necrotic areas (Figure 3c , left lower panel). In contrast, sections of untreated MMTV-wnt1 tumors (Figure 3d , upper left panel) showed luminal and myoepithelial components with a large stromal compartment and areas of glandular differentiation. As indicated by large areas of acinar differentiation with cell remnants inside the lumen, likely the result of anoikis, differentiation was further enhanced by the Am580 treatment (Figure 3d, lower left panel, arrows) . Some MMTV-wnt1 tumors from treated mice showed (Figure 3d ). As already mentioned, the differentiation of MMTV-wnt1 tumor cells by Am580 in 3D cultures (Debnath et al., 2003) induced lumen formation, most likely because of cavitation, in approximately 30% of the colonies, although no cavitation was detected in the control colonies. Moreover, this morphogenetic effect induced by the activation of RARa by Am580 was reversed by the RARa antagonists Ro-415253 (results not shown), indicating the central role that RARa has in the reversion of the transformed phenotype induced by wnt. Together, these results suggest that in the MMTV-wnt1 tumors, in addition to inhibiting proliferation, Am580 treatment also initiates a RARa-dependent process of differentiation. Tests of additional markers of differentiation confirmed these conclusions. For example, although the treatment reduced the overall level of CK-14, a basal cell marker, in MMTV-neu tumors (Figures 4a and b) , only in the MMTV-wnt1 tumors it led to its relocalization to the basal surface of acini, which appeared to have undergone cavitation (Figure 4a) . Similarly, Am580treated MMTV-wnt1 tumors, which showed acinar differentiation (Figure 4c ), had properly polarized CK-6, a luminal marker. Finally, cellular retinol-binding protein-1 (CRBP-1), a RARa target gene highly (Figures 4a  and b ), but in MMTV-wnt1 treated with Am580, it seemed to be localized to cells surrounding acini-like structures (Figure 4a ). Although not clearly evident from the immunohistochemical staining, the expression of the specifically localized CRBP-1 in Am580-treated wnt tumors must be very high, as indicated by its increased level in the immunoblots (Figure 4b ).
In searching for a possible mechanism for the observed oncogene-dependent difference of Am580 effect, we considered the published evidence implicating activated RAR in wnt pathway inhibition (Mulholland et al., 2005) , predominantly through interference with bcatenin function (Easwaran et al., 1999) . Activation of b-catenin pathway is reflected, among others, in its accumulation in the nucleus (Polakis, 2000) . To test whether Am580 affected this pathway, cells obtained from MMTV-wnt1 tumors were cultured in 3D conditions and treated with either 50 nM AM580 or vehicle control and stained for b-catenin. In the control colonies, which showed no signs of cavitation, b-catenin was localized to cell membrane, but was also present in the nuclei (Figure 4d ). Am580 treatment produced mostly cavitated colonies and profoundly reduced nuclear b-catenin (Figure 4d ). This finding suggests that overexpressed wnt-driven pathways might be normalized by the Am580 treatment, allowing tumor differentiation by Am580.
Thus, as evidenced by the reduction in pRb, increase in p27, reduction in P-Akt and activation of caspase-3, Am580 induces cell cycle arrest and apoptosis in both tumor types. In addition, in MMTV-wnt1 tumors, the treatment induces differentiation, as indicated by proper localization of CK-14, CK-6 and CRBP-1, and induction of cavitation of acinar structures. One of the induced gene, CRBP-1, is a known target of RAR, and p27 accumulation is highly sensitive to RAR activation (Radu et al., 2008) .
Is evading RARg activation the reason for antitumor effect of Am580?
To test the status of RARs and their signaling in tumors of Am580-fed mice, we measured RARa, b and g protein content in extracts of tumors derived from MMTV-neu and MMTV-wnt1 mice. As shown in Figure 5a , the level of RARb2, a known retinoid target gene, was increased in both tumor types, indicating that RAR-mediated signaling was active. However, the RARg-protein level was strongly reduced in both tumor types treated with Am580 ( Figure 5a ).
As atRA treatment, which activates all three RARs, was shown to stimulate the growth of MMTV-neu tumors (Schug et al., 2007) , whereas we showed RARa agonist to be inhibitory and to reduce the level of RARg (Figure 5a ), we wondered whether it was the RARg that, when activated by atRA, produced the deleterious effects. Immunohistochemistry of RARg in sections of MMTV-wnt1 tumors showed homogenously distributed expression throughout the tumor tissue ( Figure 5b) ; in Am580-treated tumor sections, with the exception of strong staining in the normal skin adjacent to the tumor, there was almost no RARg staining. This suggests different regulation of RARg by Am580 in normal and tumor tissue.
We attempted to probe the role of RARg in wnt1 and neu tumor-derived cells by knockdown or overexpression experiments but, so far, we did not find conditions that allowed for consistent RARg downregulation or overexpression. However, using immortalized human breast cell line, MCF-10, in which we overexpressed RARg (Figure 6a ), we showed that RARg overexpression significantly increased the proliferation rate ( Figure 6b ) and, importantly, rendered the cells resistant to the well-known atRA-mediated downregulation of pRb and upregulation of p27 (Borriello et al., 2006) (Figure 6c ). Thus, similar to wnt1 and neu tumors, the antiproliferative effect of Am580 in human cells seems to be counteracted by overexpression of RARg. Thus, in addition to the published mechanism of atRA enhancement of neu tumor growth through increase in FABP5 (Schug et al., 2007) , we identified RARg activity as another possible contributor to this effect. Importantly, we found that unlike atRA (Schug et al., 2007) , Am580 neither increased the level of FABP5 protein nor Figure S1 ).
Discussion
This work was designed to determine whether different RAR isoforms differ in their ability to provide protection from oncogene-induced mammary carcinogenesis and whether this effect is oncogene dependent. We conclude that activation of RARa by a specific agonist, Am580, significantly diminished mammary gland tumorigenicity of two oncogenes, wnt1 and neu. Moreover, we found that inhibition of proliferation and induction of apoptosis occurred in both oncogeneinduced tumors, but induction of differentiation was oncogene specific and was only detected in wnt1-induced tumors. This is important because the overall effect on tumor incidence was more pronounced in the MMTV-wnt1 model, suggesting that treatment that combines growth inhibition, induction of apoptosis and differentiation might be most effective.
Our data are more relevant when considered in the background of the poor retinoid performance in clinical trials (Paik et al., 2003) , and the recent publication by AM580 chemoprevention, oncogenes and negative RARc role Y Lu et al Schug et al. (2007) indicating that treatment of MMTVneu mice with atRA, a non-selective RAR activator, enhances neu-mammary tumor incidence and growth. Treatment with atRA was shown to change the proportion of FABP5/CRABP-II, causing PPARb/d activation at the expense of RARs, and increased proliferation and cell survival, a finding not confirmed in cells treated with Am580 ( Supplementary Figure S1) . Thus, although PPARb/d can bind several ligands Noy, 2007) , Am580 does not seem to function as its activator, a fact that provides a possible explanation for the pro-proliferative atRA effect and the inhibitory Am580 effect in MMTV-neu tumors. Another advantage of Am580 over atRA is its resistance to degradation by CYP26A1 P450 cytochromes involved in atRA catabolism to its oxo-derivatives (White et al., 1997) . These cytochromes are overexpresed in several tumor cell lines and human tumors, leading to atRA resistance (Van heusden et al., 1998; Klaassen et al., 2001; Ozpolat et al., 2002) . Thus, the use of a retinoid resistant to CYP26 regulation might help to overcome the development of retinoid resistance. However, based on our own data and on published evidence (Schneider et al., 2000; Purton et al., 2006) , we propose that active RARg is pro-proliferative and hence responsible for the enhancing atRA effect. Our findings that RARg overexpression interferes with atRA-induced expression of p27 and reduction in pRb (Figure 6c ) support this notion. Moreover, we showed that RARg level is reduced in Am580-treated tumors, whereas its level in the neighboring skin remains unaffected (Figure 5b ), suggesting a tumor-specific-RARg regulation by RARa-specific agonist. It also shows that treatment with RARa agonist might both bypass RARg activation and reduce its level. We have not yet investigated the mechanism of RARg reduction by Am580. Published evidence shows that by inhibiting phosphoinositide 3-kinase, retinoids lead to p38 activation, which in turn phosphorylates RARg and leads to its degradation (Kim et al., 2001; Gianni et al., 2002) . Whether this pathway mediates the loss of RARg in tumors from Am580-treated mice remains to be seen. The observed pro-proliferative role of RARg is in agreement with the finding in SK-BR-3 human breast cancer cell line, in which treatment with an RARg agonist, CD437, induced growth (Schneider et al., 2000) . Purton et al. (2006) have shown that the high RARg level present in primitive hematopoietic precursors wanes during cell maturation simultaneously with an increase in RARa and b. Bone marrow of RARg knockout mice showed markedly reduced numbers of hematopoietic stem cells associated with increased numbers of more mature progenitor cells, suggesting that RARg in these cells serves self-renewal and antidifferentiation functions (Purton et al., 2006) . Although it is too early to extrapolate from hematopoietic to mammary biology, it remains theoretically possible that during cycles of proliferation and involution of the mammary epithelium, a similar regulation in the expression of RARs exists in the stem/progenitor cells compartment. atRA treatment, by activating RARg, could perturb the equilibrium between progenitors and differentiated cells, increasing tumorigenicity. The observed ability of Am580 to reverse mammary gland hyperplasia lends support to this hypothesis. It should be noted, however, that growth inhibitory effects of RARg have been described (Su and Gudas, 2008, Walkley et al., 2007) , suggesting that individual RARs might have unique roles in specific tissues.
Another important aspect of our findings is the observed partial oncogene-dependent responsiveness to Am580 treatment regarding tumor incidence (Kaplan- Meier Figures 1a and b ) and tumor growth ( Figures 2b  and c) ; both were more profoundly affected in the MMTV-wnt1 model. This suggests that for better responses to retinoid therapy in breast cancer patients, they might have to be stratified according to oncogenic pathways that are activated. We propose that induction of differentiation contributes to the increased responsiveness of wnt-1 tumors to Am580. Among the indicators of Am580-induced differentiation are formation of acini-like structures with signs of anoikis of the cells in the lumen, more normal-looking acini, proper localization of cytokeratins and redistribution of CRBP-1 (Figures 3 and 4 ) Thus, although not causing full differentiation, partial differentiation by Am580 might explain its stronger antitumor effect on wnt1-induced tumors. We postulate that normalization of the mammary morphology (differentiation) in these tumors is affected through the inhibition by Am580 of the wnt pathway, as determined by relocalization of b-catenin from the nucleus to the membrane (Figure 4d ).
Taken together, our data document that two mammary carcinoma models, MMTV-neu and MMTV-wnt1, are responsive to Am580 treatment and that this response is only partially oncogene dependent. The fact 
Immunohistochemistry
Tumor samples were fixed in 10% buffered formalin for 24 h, transferred to 70% ethanol and kept at 4 1C until use. Sections were prepared from 10 tumors/group, subjected to standard antigen retrieval and incubated overnight at 4 1C with p27 (BD Transduction Labs, San Jose, CA, USA), pRb, activated caspase-3 (Cell Signaling, Danvers, MA, USA), CK-14 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), CK-6 (Covance, Princeton, NJ, USA) or RARg antibodies (Abcam, Cambridge, MA, USA) in a final concentration of 1 mg/ml. The sections were processed using VectaStain ABC Elite Kit (Vector Laboratories, Bulingame, CA, USA), and the signal was detected using Metal Enhanced DAB Substrate Kit (Pierce Laboratories, Rockford, IL, USA) and the sections were counterstained with Harris hematoxylin solution (Sigma Diagnostics, St Louis, MO, USA).
Immunoblotting
Tumor homogenates (total protein 25-50 mg) boiled in Laemmli buffer with b-mercaptoethanol were electrophoresed on 10-15% SDS polyacrylamide gels, transferred to polyvinylidine fluoride membranes (Hybond-P; Amersham Biosciences, Upsala, Sweden), blocked with 5% non-fat dried milk and incubated with the primary antibody in 3% non-fat dry milk solution diluted as specified: anti-RARa, b and g, 1:500 (Abcam), anti-Akt and p-Akt, 1:1000 (Cell Signaling), anti-CK-14 and CK-18, 1:1000 (Santa Cruz Biotechnology), anti-FABP5, 1:500 (BioVendor, Candler, NC, USA), antitubulin and anti-vinculin, 1:3000 (Sigma). Some membranes were stripped and re-probed.
Cell lines and 3D cultures MMTV-wnt1 cell lines were generated from fragments of tumors from untreated MMTV-wnt1 mice after digestion with collagenase (1.5 mg/ml collagenase, 25 mg/ml bovine serum albumin in phosphate-buffered saline with Ca 2 þ and Mg 2 þ ) at 37 1C for 30-45 min with gentle agitation. The 3D cultures were prepared and maintained as described by Debnath et al. (2003) . MCF-10A cells were generously provided by Dr Brugge and maintained as described by Debnath et al., (2003) (for details see Supplementary Data) . The apoptotic index was performed by ethidium bromide (Gantenbein-Ritter et al., 2008;  for details see Supplementary Data) .
Proliferation assay MCF-10A (2 Â 10 4 ) control cells or overexpressing RARg were seeded in triplicates in six-well culture dishes. After 24 h, cells were washed with phosphate-buffered saline, incubated in 2 ml of Dulbecco's modified Eagle's medium/F12 culture medium, and detached and counted every 24 h. Statistical significance was determined by t-test. pRb and p27 expression was tested by immunofluorescence analysis of control MCF-10A monolayers and monolayers stably transfected with pSG5-RARg expression vector, using the same antibodies described for the immunohistochemistry analysis.
